Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. To know more visit : http://tinyurl.com/ja4bvwa

1. Anti- hypertensive Therapeutics in Asia-
Pacific Markets to 2021- Increasing
Prevalence of Hypertension Drives Market
Growth despite Weak Pipeline
The Global Anti- hypertensive Therapeutics market is
expected to increase in value at a CAGR of 1.2% from $517
million to $561 million.
Click Here To Check Complete Report

2. Hypertension is a chronic medical condition characterized by elevated blood pressure in
the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a
Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-
Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a
substantial contributor to healthcare costs and a major cause of morbidity. Despite this,
awareness of hypertension is low among physicians, patients, and the public alike, leading
to poor blood pressure control.
The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme
Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB),
beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using
monotherapy and combination therapy (including fixed-dose combinations) varies from
country to country. The most commonly prescribed drugs in the CCB class are amlodipine
and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan,
irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril,
perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate
the ACEIs.
Summary of the Report:

3. • Hypertension prevalence is a prominent contributor to market size in the assessed
countries. The market is mostly dominated by generics, and there are only a few patented
products.
• Will generics continue to dominate treatment?
• How do the elderly populations and their associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in
various stages of development, dominated by small molecules.
• Will the upcoming molecules change the treatment paradigm in the near future?
• How will the weak pipeline affect the market?
• How do failure rates vary by product stage of development, molecule type, and
mechanism of action?
• How do other factors such as average trial duration and trial size influence the costs and
risks associated with product development?
• Over the 2014–2021 forecast periods, the APAC anti-hypertensive therapeutics market is
expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9
billion. Growth is projected to vary considerably across the four assessed markets.
Scope of the Report:
Download Sample
Brochure

4. • This report will enable you to –
• Understand the clinical context of hypertension by considering symptoms, etiology,
pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment
options.
• Identify the therapeutic strategies, products, and companies that dominate the current
marketed products landscape, and recognize gaps.
• Appreciate key anti-hypertensive pipeline trends in molecule type, administration route,
mechanism of action, and novelty.
• Consider market opportunities and potential risks by examining trends in anti-hypertensive
clinical trial size, duration, and failure rate by stage of development, molecule type, and
mechanism of action.
• Compare treatment usage patterns, annual therapy costs, and market growth projections
for the China, India, Australia, and Japan.
• Discover trends in licensing and co-development deals concerning anti-hypertensive
products and identify the major strategic consolidations that have shaped the commercial
landscape.
Reasons to Buy:
Make an Inquiry
Before Buying

5. Anti- hypertensive Therapeutics in Asia-
Pacific Markets to 2021- Increasing
Prevalence of Hypertension Drives
Market Growth despite Weak Pipeline
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the global Anti- hypertensive Therapeutics in Major Developed Markets and
future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of Anti-
hypertensive Therapeutics
Markets to 2021 Report